Tech Company Financing Transactions
Scioto Biosciences Funding Round
Genome & Company participated in a $26.5 million Series B funding round for Scioto Biosciences. The funding round closed on 8/12/2020.
Transaction Overview
Company Name
Announced On
8/12/2020
Transaction Type
Venture Equity
Amount
$26,500,000
Round
Series B
Investors
Genome & Company (Pae Jisoo)
Proceeds Purpose
The funding will continue to support clinical development of Scioto's lead drug candidate, SB-121, which targets disorders related to the gut-brain axis like Autism Spectrum Disorder (ASD) as well as disorders related to gut-injury such as Necrotizing Enterocolitis (NEC) which affects premature infants.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1800 N. Capitol Ave. Indiana Center for Biomedical Innovatio E504
Indianapolis, IN 46202
USA
Indianapolis, IN 46202
USA
Phone
Website
Email Address
Overview
The Scioto Platform is a novel formulation that primes the colony-forming mechanisms of probiotic bacteria by combining beneficial bacteria with polysaccharide microspheres. These natural mechanisms induce 'biofilm' formation, enhance probiotic function and allow for non-spore forming bacteria to survive passage through the gastrointestinal system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joe Trebley
Chief Financial Officer
James Schulz
Chief Operating Officer
Kevin Meyer
Chief Scientific Officer
Mark Heiman
Browse more venture capital transactions:
Prev: 8/12/2020: WayScript venture capital transaction
Next: 8/13/2020: InnovHeart venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs